Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (7,758,077) $ (21,182,040)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued interest/dividends 4,496
Amortization of debt discount 608,460
Amortization of intangible assets
Gain on sale of marketable securities 3,649 (41,447)
Unrealized loss on marketable securities 145 41,447
Gain on forgiveness of debt (180,258)
Stock based compensation    
Options modification expense 15,036,051
Options issued to key employees 208,332
Options issued to non-employees 4,916
Restricted stock units to non-employees 15,998
Change in assets and liabilities    
Prepaid Expenses (265,060) (557,279)
Trade and Other Payables 1,854,909 (1,988,204)
Operating Leases 943 278
Net cash used by operating activities (5,934,245) (8,258,496)
Cash flows from investing activities:    
Purchases of marketable securities (6,548) (10,137)
Proceeds from sale of marketable securities 6,500,000 9,983,176
Net cash received in business combination 1,380,852
Net cash provided by investing activities 6,493,452 11,353,891
Cash flows from financing activities    
Consumed by the payoff of the line of credit – related party (3,062,444)
Net proceeds from line of credit - related party 120,000
Net proceeds from note payable 1,826,137
Net cash provided (used) by financing activities (1,116,307)
Net increase in cash 559,207 1,979,088
Cash at beginning of period 555,567 148,284
Cash at end of period 1,115,174 2,127,372
Supplemental cash flow information    
Interest 271,800
Income Taxes
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Operating lease right-of-use asset obtained in exchange for lease obligation 53,196
Investment in Oravax, Inc. included in trade and other payables. $ 1,500,000